Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AEROLATE vs ALBUTEROL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP, leading to bronchodilation.
FDA-approved: Treatment of asthma and chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, bradycardia in preterm infants
Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease,Prevention of exercise-induced bronchospasm,Off-label: Acute hyperkalemia (via nebulization)
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
2.5 mg (0.5 m L of 0.5% solution) via nebulization every 4-6 hours as needed; or 1-2 inhalations (90 mcg/inhalation) from a metered-dose inhaler every 4-6 hours as needed.
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Terminal elimination half-life is 3.8-6.0 hours. In patients with asthma, the half-life is similar, but clinical effect duration is shorter due to rapid redistribution from the receptor site.
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally.
Primarily metabolized via sulfotransferase (SULT1A3) to inactive sulfate conjugate; minor hepatic metabolism by CYP450 enzymes.
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
Primarily renal: approximately 60-70% of the dose is excreted in urine as unchanged drug and metabolites (sulfate conjugate) within 24 hours. Fecal excretion accounts for less than 10%.
65% bound to albumin
Approximately 52-65% bound to human serum albumin and alpha-1-acid glycoprotein.
2.5 L/kg (extensive tissue distribution, suggests high lung penetration)
Approximately 1.4-2.0 L/kg. This relatively large Vd indicates extensive distribution into tissues, including lung parenchyma.
Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition)
Inhaled: 10-20% of the dose reaches the lungs systemically; Oral: approximately 28-40% (due to first-pass metabolism to sulfate conjugate); Subcutaneous: nearly 100%.
No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction.
No dosage adjustment required for renal impairment.
Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance.
No specific guidelines; use with caution in severe hepatic impairment due to potential for increased systemic exposure.
Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group.
Nebulized: 0.05-0.15 mg/kg/dose (minimum 1.25 mg) every 4-6 hours as needed. MDI: 1-2 inhalations (90 mcg/inhalation) every 4-6 hours as needed. Maximum: 12 inhalations/day.
No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression.
Initiate at lower end of dosing range; monitor for tremors, tachycardia, and hypertension. No specific dose adjustment required.
No FDA black box warning.
None.
Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/m L).,Risk of toxicity at high levels: seizures, arrhythmias, death.,Use with caution in patients with hepatic impairment, heart failure, fever, or elderly.,Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism.
Paradoxical bronchospasm may occur with excessive use,Cardiovascular effects: increased heart rate, hypertension, arrhythmias,Hypokalemia may occur with high doses,Immediate hypersensitivity reactions possible,Use caution in patients with cardiovascular disorders, hyperthyroidism, diabetes, or seizure disorders
Hypersensitivity to theophylline or any component.,Active peptic ulcer disease.,Uncontrolled seizure disorders.
Hypersensitivity to albuterol or any component of the formulation
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended.
No clinically significant food interactions. Caffeine may potentiate stimulant effects; avoid excessive caffeine intake.
AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation.
FDA Pregnancy Category C. In first trimester, no increased risk of major congenital anomalies based on human data. Second and third trimesters: risk of maternal tachycardia, hyperglycemia; fetal tachycardia, hypoglycemia at birth if used near term. Possible association with gastroschisis in first trimester from some studies, but not confirmed.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Peak milk levels occur 1-2 hours after maternal dosing. Estimated infant dose is about 1-10% of maternal weight-adjusted dose. Caution: irritability and jitteriness reported in breastfed infants. Avoid breastfeeding if maternal serum theophylline levels exceed 20 mcg/m L.
Excreted into breast milk in low concentrations; M/P ratio not established. Limited data suggest no adverse effects in infants. American Academy of Pediatrics considers compatible with breastfeeding. Use with caution in preterm infants or those with tachycardia.
Pregnancy may increase theophylline clearance (especially in second and third trimesters) due to increased renal perfusion and hepatic metabolism. Dose adjustments often required to maintain therapeutic levels. Initiate at standard dose and titrate based on serum levels and clinical response. Postpartum clearance decreases rapidly; doses should be reduced to pre-pregnancy levels within 2-4 weeks after delivery.
No specific dose adjustment required for pregnancy. Pharmacokinetics may be altered due to increased plasma volume and renal clearance, but clinical significance is minimal. Use lowest effective dose to control symptoms.
AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels.
Monitor for paradoxical bronchospasm; use with caution in patients with cardiovascular disorders due to beta-adrenergic stimulation; may cause hypokalemia with high doses; combine with ipratropium for acute exacerbations; not recommended for long-term control without anti-inflammatory therapy.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism.,Keep a list of all medications you take, including over-the-counter drugs and herbal supplements.
Use only as prescribed; do not exceed recommended dose.,Rinse mouth after use to prevent oral candidiasis (if using with corticosteroid), but albuterol alone does not require rinsing.,Seek emergency care if symptoms worsen or inhaler provides less relief.,Shake inhaler well before each use; use spacer if available for better delivery.,Monitor for palpitations, tremors, or nervousness; report if severe.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AEROLATE vs ALBUTEROL, answered by our medical review team.
AEROLATE is a Bronchodilator that works by Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.. ALBUTEROL is a Beta-2 Adrenergic Agonist (Bronchodilator) that works by Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP, leading to bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AEROLATE and ALBUTEROL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AEROLATE is: For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.. The standard adult dose of ALBUTEROL is: 2.5 mg (0.5 m L of 0.5% solution) via nebulization every 4-6 hours as needed; or 1-2 inhalations (90 mcg/inhalation) from a metered-dose inhaler every 4-6 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AEROLATE and ALBUTEROL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AEROLATE is classified as Category C. AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theo. ALBUTEROL is classified as Category C. FDA Pregnancy Category C. In first trimester, no increased risk of major congenital anomalies based on human data. Second and third trimesters: risk of maternal tachycardia, hyperg. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.